Over-expressing transporters associated with antigen processing increases antitumor immunity response in prostate cancer

Cellular Immunology

Volumn 279, Issue 2, 2012, Pages 167-173

  Qiu, Tao ^a   Wang, Lei ^a   Liu, Xiu Heng ^a   Weng, Xiao Dong ^a   Kuang, You Lin ^a   Chen, Zhi Yuan ^a   Chen, Hui ^a   Zhu, Heng Cheng ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Dendritic cell; Lentivirus; Prostate cancer; TAP1

Indexed keywords

CD3 ANTIGEN; CD38 ANTIGEN; HLA ANTIGEN CLASS 1; TAPASIN; TRANSCRIPTION FACTOR FOXP3; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD3; ANTIGENS, CD38; ANTIGENS, CD8; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; FORKHEAD TRANSCRIPTION FACTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LENTIVIRUS; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS; TUMOR MICROENVIRONMENT;

LENTIVIRUS;

EID: 84871019512     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.10.004     Document Type: Article

References (47)

1. Miller A.M., Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol. Immunother. 2005, 56:81-87.
2. Mottet N., Bellmunt J., Bolla M., et al. EAU guidelines on prostate cancer. part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 2011, 59:572-583.
3. Lubaroff D.M. Prostate cancer vaccines in clinical trials. Expert Rev. Vaccines 2012, 11:857-868.
4. May K.F., Gulley J.L., Drake C.G., et al. Prostate cancer immunotherapy. Clin. Cancer Res. 2011, 17:5233-5238.
5. Cha E., Fong L. Immunotherapy for prostate cancer: biology and therapeutic approaches. J. Clin. Oncol. 2011, 29:3677-3685.
6. Bilusic M., Heery C., Madan R.A. Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Expert Rev. Vaccines 2011, 29:6485-6497.
7. Flemming A. Immunotherapy: a vaccine for prostate cancer?. Nat. Rev. Cancer 2011, 11:539.
8. Melief C.J., Finn O.J. Cancer immunology. Curr. Opin. Immunol. 2011, 23:234-236.
9. Seliger B., Stoehr R., Handke D., et al. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol. Immunother. 2010, 59:529-540.
10. Seliger B., Ritz U., Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int. J. Cancer 2006, 118:129-138.
11. Sanda M.G., Restifo N.P., Walsh J.C., et al. Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst. 1995, 87:280-285.
12. Lee H.M., Timme T.L., Thompson T.C. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res. 2000, 60:1927-1933.
13. Setiadi A.F. Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas. Cancer Res. 2005, 65:7485-7492.
14. Parcej D., Tampe R. ABC proteins in antigen translocation and viral inhibition. Nat. Chem. Biol. 2010, 6:572-580.
15. Blanchard N., Shastri N. Cross-presentation of peptides from intracellular pathogens by MHC class I molecules. Ann. N. Y. Acad. Sci. 2010, 1183:237-250.
16. Amigorena S., Savina A. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr. Opin. Immunol. 2010, 22:109-117.
17. Zhang Q.-J., Seipp R.P., Chen S.S., et al. TAP expression reduces IL-10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma. Int. J. Cancer 2007, 120:1935-1941.
18. Lou Y., Seipp R., Cai B., et al. Tumour immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1. Expert Rev. Vaccines 2007, 25:2331-2339.
19. Vitalis T.Z., Zhang Q.J., Alimonti J., et al. Using the TAP component of the antigen-processing machinery as a molecular adjuvant. PLoS Pathog. 2005, 1:e36.
20. Lou Y., Vitalis T.Z., Basha G., et al. Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res. 2005, 65:7926-7933.
21. Gabathuler R., Reid G., Kolaitis G., et al. Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J. Exp. Med. 1994, 180:1415-1425.
22. Alimonti J., Zhang Q.J., Gabathuler R., et al. TAP expression provides a general method for improving the recognition of malignant cells In vivo. Nat. Biotechnol. 2000, 18:515-520.
23. + and CD4+ T-cell responses. J. Virol. 2008, 82:86-95.
24. Ageichik A., Collins M.K., Dewannieux M. Lentivector targeting to dendritic cells. Mol. Ther. 2008, 16:1008-1009.
25. Kitamura H., Torigoe T., Asanuma H., et al. Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J. Urol. 2007, 178:692-696.
26. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 10:909-915.
27. Yi H., Yu X., Guo C., et al. Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens. Cancer Immunol. Immunother. 2011, 60:349-360.
28. Algarra I., Garcia-Lora A., Cabrera T., et al. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol. Immunother. 2004, 53:904-910.
29. + T lymphocytes in prostate, and quantification of CD8 and interferon-gamma mRNA in prostate tissue specimens. BJU Int. 2002, 90:748-753.
30. Blades R.A., Keating P.J., McWilliam L.J., et al. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995, 46:681-686.
31. Koch J., Guntrum R., Heintke S., et al. Functional dissection of the transmembrane domains of the transporter associated with antigen processing (TAP). J. Biol. Chem. 2004, 279:10142-10147.
32. Procko E., Raghuraman G., Wiley D.C., et al. Identification of domain boundaries within the N-termini of TAP1 and TAP2 and their importance in tapasin binding and tapasin-mediated increase in peptide loading of MHC class I. Immunol. Cell Biol. 2005, 83:475-482.
33. Tan P., Kropshofer H., Mandelboim O., et al. Recruitment of MHC class I molecules by tapasin into the transporter associated with antigen processing-associated complex is essential for optimal peptide loading. J. Immunol. 2002, 168:1950-1960.
34. Qifeng S., Bo C., Xingtao J., et al. Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics. J. Thorac. Cardiovasc. Surg. 2011, 141:808-814.
35. Han W., Pan H., Jiang L., et al. A novel approach to rescue immune escape in oral squamous cell carcinoma: combined use of interferon-gamma and LY294002. Oncol. Rep. 2011, 25:181-187.
36. Leibowitz M.S., Andrade Filho P.A., Ferrone S., et al. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol. Immunother. 2011, 60:525-535.
37. Jefferies W.A., Kolaitis G., Gabathuler R. IFN-gamma-induced recognition of the antigen-processing variant CMT.64 by cytolytic T cells can be replaced by sequential addition of beta 2 microglobulin and antigenic peptides. J. Immunol. 1993, 151:2974-2985.
38. Scholz C., Tampe R. The peptide-loading complex-antigen translocation and MHC class I loading. Biol. Chem. 2009, 390:783-794.
39. Lou Y., Basha G., Seipp R.P., et al. Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival. Clin. Cancer Res. 2008, 14:1494-1501.
40. Beismann-Driemeyer S., Tampe R. Function of the antigen transport complex TAP in cellular immunity. Angew. Chem. Int. Ed. Engl. 2004, 43:4014-4031.
41. Basha G., Lizee G., Reinicke A.T., et al. MHC class I endosomal and lysosomal trafficking coincides with exogenous antigen loading in dendritic cells. PLoS ONE 2008, 3:e3247.
42. Sconocchia G., Titus J.A., Mazzoni A., et al. CD38 triggers cytotoxic responses in activated human natural killer cells. Blood 1999, 94:3864-3871.
43. Halenius A., Hauka S., Dolken L., et al. Human cytomegalovirus disrupts the major histocompatibility complex class I peptide-loading complex and inhibits tapasin gene transcription. J. Virol. 2011, 85:3473-3485.
44. Alexopoulou L., Holt A.C., Medzhitov R., et al. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature 2001, 413:732-738.
45. Segura M.M., Kamen A.A., Garnier A. Overview of current scalable methods for purification of viral vectors. Methods Mol. Biol. 2011, 737:89-116.
46. Setiadi A.F., David M.D., Seipp R.P., et al. Epigenetic control of the immune escape mechanisms in malignant carcinomas. Mol. Cell. Biol. 2007, 27:7886-7894.
47. Setiadi A.F., David M.D., Chen S.S., et al. Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas. Cancer Res. 2005, 65:7485-7492.